BluePointe Capital Management’s AbbVie ABBV Stock Holding History

BluePointe Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$298K	Buy	+1,424	New	+$277K	0.11%	101

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

BluePointe Capital Management's ABBV Position: Q1 2025 in Review

BluePointe Capital Management opened a new position in AbbVie (ABBV) in Q1 2025: 1,424 shares worth $298K. The stake represents 0.11% of the portfolio and ranks #101 among its holdings.

3,826 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

BluePointe Capital Management held 1,424 shares of AbbVie worth $298K as of Q1 2025.
AbbVie was a new BluePointe Capital Management position in Q1 2025.
AbbVie made up 0.11% of BluePointe Capital Management's portfolio in Q1 2025, its #101 holding.
3,826 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on BluePointe Capital Management's 13F filing for Q1 2025, filed 2 May 2025.